In contrast, kallistatin ameliorates renal fibrosis by attenuating EMT and fibroblast activation through inhibition of the Wnt/β-catenin and TGF-β signaling pathway (Yiu et al., 2021; Yuan et al., 2022b). The gene discussed is TGFB1; the disease is renal fibrosis.